Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stallergenes, a biopharmaceutical company, and Solvay Pharmaceuticals Marketing and Licensing, a subsidiary of Solvay Group, have signed an exclusive partnership agreement for the promotion and distribution of Stallergenes diagnostic and treatment products in Russia and the Commonwealth of Independent States.
Subscribe to our email newsletter
The main products in Stallergenes’s injectable and sublingual ranges will soon be the subject of registration applications. This partnership reportedly enables Stallergenes to meet more than 80% of the needs of allergy sufferers in Russia and the Commonwealth of Independent States by 2011.
Albert Saporta, chairman and CEO of Stallergenes, said: “We’re delighted to be teaming up with Solvay Pharmaceuticals to target the potential growth this new market represents. Thanks to its franchise and its considerable expertise recognized by allergy specialists, Solvay Pharmaceuticals will enable us to promote the desensitization standardized products, and notably the sublingual route, and their benefits for patients.”